-
1Academic Journal
Authors: Shosha E.I. Dekker, Aswin Verhoeven, Daria Frey, Darius Soonawala, Dorien J.M. Peters, Oleg A. Mayboroda, Johan W. de Fijter
Source: Am J Nephrol
American journal of nephrology. 2022. Vol. 53, № 6. P. 470-480Subject Terms: Male, расчетная скорость клубочковой фильтрации, биомаркеры, Kidney, Citric Acid, аутосомно-доминантная поликистозная болезнь почек, Autosomal dominant polycystic kidney disease, 03 medical and health sciences, 0302 clinical medicine, Humans, моча, 10. No inequality, 2. Zero hunger, Patient-Oriented, Translational Research: Research Article, Progression, Biomarker, Middle Aged, Polycystic Kidney, Autosomal Dominant, 6. Clean water, 3. Good health, Estimated glomerular filtration rate slope, Urine metabolites, Disease Progression, метаболиты, Female, Inositol, Glomerular Filtration Rate
File Description: application/pdf
-
2Academic Journal
Authors: Vishneva, K. A., Kazantsev, S. E., Nikitaeva, A. P., Vishneva, E. M., Вишнева, К. А., Казанцев, С. Е., Никитаева, А. П., Вишнева, Е. М.
Source: Сборник статей
Subject Terms: CHRONIC KIDNEY DISEASE, ESTIMATED GLOMERULAR FILTRATION RATE, CARDIOVASCULAR DISEASES, CYSTATIN C, ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК, РАСЧЕТНАЯ СКОРОСТЬ КЛУБОЧКОВОЙ ФИЛЬТРАЦИИ, СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ, ЦИСТАТИН C
File Description: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения : Сборник статей IX Международной научно-практической конференции молодых ученых и студентов, 17-18 апреля 2024 г. Т. 1.; http://elib.usma.ru/handle/usma/21153
Availability: http://elib.usma.ru/handle/usma/21153
-
3Academic Journal
Source: Počki, Vol 10, Iss 2, Pp 54-57 (2021)
KIDNEYS; Vol. 10 No. 2 (2021); 54-57
Почки-Počki; Том 10 № 2 (2021); 54-57
Нирки-Počki; Том 10 № 2 (2021); 54-57Subject Terms: раннє тренування для збільшення споживання води (примусова гідратація) при ХХН, розрахункова швидкість клубочкової фільтрації, функціональний нирковий резерв, early coaching to increase water intake in ckd, egfr, renal functional reserve, 03 medical and health sciences, 0302 clinical medicine, ранняя тренировка по увеличению потребления воды (принудительная гидратация) при ХБП, расчетная скорость клубочковой фильтрации, функциональный резерв почек, early coaching to increase water intake in CKD, eGFR, renal functional reserve, RC870-923, Diseases of the genitourinary system. Urology, 3. Good health
File Description: application/pdf
-
4Academic Journal
Authors: S.V. Kushnirenko
Source: Сучасна педіатрія. Україна; № 6(102) (2019): Сучасна педіатрія. Україна; 12-17
Modern Pediatrics. Ukraine; No. 6(102) (2019): Modern pediatrics. Ukraine; 12-17
Современная педиатрия. Украина; № 6(102) (2019): Современная педиатрия. Украина; 12-17Subject Terms: цистатин С, расчетная скорость клубочковой фильтрации, estimated glomerular filtration rate, children, хроническая болезнь почек, cystatin C, розрахункова швидкість клубочкової фільтрації, хронічна хвороба нирок, діти, дети, chronic kidney disease, 3. Good health
File Description: application/pdf
-
5Academic Journal
Authors: N. I. Ryumshina, I. V. Zyubanova, A. E. Sukhareva, M. A. Manukyan, N. D. Anfinogenova, A. M. Gusakova, A. Yu. Falkovskaya, W. Yu. Ussov, Н. И. Рюмшина, И. В. Зюбанова, А. Е. Сухарева, М. А. Манукян, Н. Д. Анфиногенова, А. М. Гусакова, А. Ю. Фальковская, В. Ю. Усов
Source: Siberian Journal of Clinical and Experimental Medicine; Том 37, № 1 (2022); 57-66 ; Сибирский журнал клинической и экспериментальной медицины; Том 37, № 1 (2022); 57-66 ; 2713-265X ; 2713-2927
Subject Terms: расчетная скорость клубочковой фильтрации, renal dysfunction markers, magnetic resonance imaging, absolute renal volume, normalized renal volume, estimated glomerular filtration rate, маркеры дисфункции почек, магнитно-резонансная томография, абсолютный объем почек, нормализованный объем почек
File Description: application/pdf
Relation: https://www.sibjcem.ru/jour/article/view/1355/686; Chiu N., Lauffenburger J.C., Franklin J.M., Choudhry N.K. Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. Hypertens. Res. 2021;4(11):1471–1482. DOI:10.1038/s41440-021-00739-6.; Sinnott S.J., Smeeth L., Williamson E., Douglas I.J. Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995–2015. BMJ. 2017;358:j3984. DOI:10.1136/bmj.j3984.; Искендеров Б.Г. Кардиоренальный синдром у кардиологических больных. Пенза; 2013:160.; Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J. Hypertens. 2018;36(10):1953–2041. DOI:10.1097/HJH.0000000000001940.; Caroli A., Remuzzi A., Lerman L.O. Basic principles and new advances in kidney imaging. Kidney Int. 2021;1009(5):1001–1011. DOI:10.1016/j.kint.2021.04.032.; Чазова И.Е., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6–31. DOI:10.26442/2075082X.2019.1.190179.; Мельникова Л.В., Осипова Е.В. Поражение почек при эссенциальной артериальной гипертензии: патогенетические основы ранней диагностики. Артериальная гипертензия. 2019;25(1):6–13. DOI:10.18705/1607-419X-2019-25-1-6-13.; Рюмшина Н.И., Лукьяненок П.И., Мордовин В.Ф., Усов В.Ю. Использование антропометрической оценки почек и надпочечников методами МР-томографии для прогнозирования эффективности ренальной симпатической денервации почечных артерий у пациентов с медикаментозно-резистентной артериальной гипертонией. Медицинская визуализация. 2017;21(4):58–64. DOI:10.24835/1607-0763-2017-4-58-64.; Roseman D.A., Hwang S.J., Oyama-Manabe N., Chuang M.L., O’Donnell C.J., Manning W.J. et al. Clinical associations of total kidney volume: The Framingham Heart Study. Nephrol. Dial. Transplant. 2017;32(8):1344–1350. DOI:10.1093/ndt/gfw237.; Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351(13):1296–1305. DOI:10.1056/NEJMoa041031.; Noda Y., Ito K., Kanki A., Tamada T., Yamamoto A., Kazuya Y. et al. Measurement of renal cortical thickness using noncontrast-enhanced steady-state free precession MRI with spatially selective inversion recovery pulse: Association with renal function. J. Magn. Reson. Imaging. 2015;41(6):1615–1621. DOI:10.1002/jmri.24719.; Zhou H., Yang M., Jiang Z., Ding J., Di J., Cui L. Renal hypoxia: An important prognostic marker in patients with chronic kidney disease. Am. J. Nephrol. 2018;48(1):46–55. DOI:10.1159/000491551.; Hommos M.S., Glassock R.J., Rule A.D. Structural and functional changes in human kidneys with healthy aging. J. Am. Soc. Nephrol. 2017;28(10):2838–2844. DOI:10.1681/ASN.2017040421.; Фальковская А.Ю., Мордовин В.Ф., Рюмшина Н.И., Пекарский С.Е., Рипп Т.М., Манукян М.А. и др. Влияние ренальной денервации на МРТ-признаки повреждения сосудистой стенки у больных резистентной артериальной гипертензией в сочетании с сахарным диабетом 2-го типа. Артериальная гипертензия. 2020;26(5):552– 563. DOI:10.18705/1607-419X-2020-26-5-552-563.; Georgianos P.I., Agarwal R. Resistant hypertension in chronic kidney disease (CKD): Prevalence, treatment particularities, and research agenda. Curr. Hypertens. Rep. 2020;22(10):84. DOI:10.1007/s11906-020-01081-x.; Nakazato T., Ikehira H., Imasawa T. Determinants of renal shape in chronic kidney disease patients. Clin. Exp. Nephrol. 2016;20(5):748– 756. DOI:10.1007/s10157-015-1220-1.; Jiang K., Ferguson C.M., Lerman L.O. Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques. Transl. Res. 2019;209:105–120. DOI:10.1016/j.trsl.2019.02.009.; Sasaki T., Tsuboi N., Okabayashi Y., Haruhara K., Kanzaki G., Koike K. et al. Synergistic impact of diabetes and hypertension on the progression and distribution of glomerular histopathological lesions. Am. J. Hypertens. 2019;32(10):900–908. DOI:10.1093/ajh/hpz059.; Müller A., Meier M. Assessment of renal volume with MRI: Experimental protocol. Method. Mol. Biol. 2021;2216:369–382. DOI:10.1007/978-1-0716-0978-1_21.; Matsuo M., Yamagishi F., Higuchi A. A pilot study of prediction of creatinine clearance by ellipsoid volumetry of kidney using noncontrast computed tomography. JMA J. 2019;2(1):60–66. DOI:10.31662/jmaj.2018-0021.; Korkmaz M., Aras B., Güneyli S., Yılmaz M. Clinical significance of renal cortical thickness in patients with chronic kidney disease. Ultrasonography. 2018;37(1):50–54. DOI:10.14366/usg.17012.; Wang X., Vrtiska T.J., Avula R.T., Walters L.R., Chakkera H.A., Kremers W.K. et al. Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney. Kidney Int. 2014;85(3):677–685. DOI:10.1038/ki.2013.359.; Bax L., van der Graaf Y., Rabelink A.J., Algra A., Beutler J.J., Mali W.P. et al. Influence of atherosclerosis on age-related changes in renal size and function. Eur. J. Clin. Invest. 2003;33(1):34–40. DOI:10.1046/j.1365-2362.2003.01091.x.; https://www.sibjcem.ru/jour/article/view/1355
-
6Academic Journal
Authors: A. Yu. Zemchenkov, R. P. Gerasimchuk, A. B. Sabodash, K. A. Vishnevskii, G. A. Zemchenkov, A. M. Omelchenko, N. N. Kulaeva, I. N. Konakova, A. A. Yakovenko, A. Sh. Rumyantsev, А. Ю. Земченков, Р. П. Герасимчук, А. Б. Сабодаш, К. А. Вишневский, Г. А. Земченков, А. М. Омельченко, Н. Н. Кулаева, И. Н. Конакова, А. А. Яковенко, А. Ш. Румянцев
Source: Russian Journal of Transplantology and Artificial Organs; Том 20, № 2 (2018); 47-60 ; Вестник трансплантологии и искусственных органов; Том 20, № 2 (2018); 47-60 ; 1995-1191 ; 10.15825/1995-1191-2018-2
Subject Terms: расчетная скорость клубочковой фильтрации, risk assessment, mortality prediction, estimated glomerular fi ltration rate, шкала рисков, предсказание летальности
File Description: application/pdf
Relation: https://journal.transpl.ru/vtio/article/view/882/709; Rivara MB, Mehrotra R. Timing of Dialysis Initiation: What Has Changed Since IDEAL? Semin. Nephrol. 2017; 37 (2): 181–193. doi:10.1016/j.semnephrol.2016.12.008.; Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB et al. IDEAL Study. A randomized, controlled trial of early versus late initiation of dialysis. N. Engl. J. Med. 2010; 363 (7): 609–619. doi:10.1056/ NEJMoa1000552.; O’Hare AM, Wong SP, Yu MK, Wynar B, Perkins M, Liu CF et al. Trends in the Timing and Clinical Context of Maintenance Dialysis Initiation. J. Am. Soc. Nephrol. 2015; 26 (8): 1975–1981. doi:10.1681/ASN.2013050531.; Higuchi S, Nakaya I, Yoshikawa K, Chikamatsu Y, Sada K, Yamamoto S et al. Potential Benefi t Associated With Delaying Initiation of Hemodialysis in a Japanese Cohort. Kidney Int. Reports. 2017; 2 (4): 594–602. doi:10.1016/j.ekir.2017.01.015.; Susantitaphong P, Altamimi S, Ashkar M, Balk EM, Stel VS, Wright S, Jaber BL. GFR at initiation of dialysis and mortality in CKD: A meta-analysis. Am. J. Kidney Dis. 2012; 59 (6): 829–840. doi:10.1053/j.ajkd.2012.01.015.; Sood MM, Manns B, Dart A, Hiebert B, Kappel J, Komenda P et al. Canadian Kidney Knowledge Translation and Generation Network (CANN-NET). Variation in the level of eGFR at dialysis initiation across dialysis facilities and geographic regions. Clin. J. Am. Soc. Nephrol. 2014; 9 (10): 1747–1756. doi:10.2215/CJN.12321213.; Slinin Y, Guo H, Li S, Liu J, Morgan B, Ensrud K et al. Provider and care characteristics associated with timing of dialysis initiation. Clin. J. Am. Soc. Nephrol. 2014; 9 (2): 310–317. doi:10.2215/CJN.04190413.; Floege J, Gillespie IA, Kronenberg F, Anker SD, Gioni I, Richards S et al. Development and validation of a predictive mortality risk score from a European hemodialysis cohort. Kidney Int. 2015; 87 (5): 996–1008. doi:10.1038/ki.2014.419.; Земченков АЮ, Вишневский КА, Сабодаш АБ, Герасимчук РП, Ананьева АО, Конакова ИН и др. Сроки начала и другие факторы на старте диализа, влияющие на выживаемость: Санкт-Петербургский регистр пациентов на заместительной почечной терапии. Нефрология и диализ. 2017; 19 (2): 255–270.; Rebollo Rubio A, Morales Asencio JM, Eugenia Pons Raventos M. Depression, anxiety and health-related quality of life amongst patients who are starting dialysis treatment. J. Ren. Care. 2017; 43 (2): 73–82. doi:10.1111/jorc.12195.; Komenda P, Gavaghan MB, Garfi eld SS, Poret AW, Sood MM. An economic assessment model for in-center, conventional home, and more frequent home hemodialysis. Kidney Int. 2012; 81 (3): 307–313. doi:10.1038/ ki.2011.338.; Строков АГ, Гуревич КЯ, Ильин АП, Денисов АЮ, Земченков АЮ, Андрусев АМ и др. Лечение пациентов с хронической болезнью почек 5-й стадии (ХБП 5) методами гемодиализа и гемодиафильтрации. Клинические рекомендации. Нефрология. 2017; 21 (3): 92–111.; Selim G, Stojceva-Taneva O, Spasovski G, Tozija L, Grozdanovski R, Georgievska-Ismail L et al. Timing of nephrology referral and initiation of dialysis as predictors for survival in hemodialysis patients: 5-year followup analysis. Int. Urol. Nephrol. 2015; 47 (1): 153–160. doi:10.1007/s11255-014-0794-y.; Wagner M, Ansell D, Kent DM, Griffi th JL, Naimark D, Wanner C et al. Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am. J. Kidney Dis. 2011; 57 (6): 894–902. doi:10.1053/j.ajkd.2010.12.023.; Couchoud C, Labeeuw M, Moranne O, Allot V, Esnault V, Frimat L et al. French Renal Epidemiology and Information Network (REIN) registry. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol. Dial. Transplant. 2009; 24 (5): 1553–1561. doi:10.1093/ndt/gfn698.; Cohen LM, Ruthazer R, Moss AH, Germain MJ. Predicting six-month mortality for patients who are on maintenance hemodialysis. Clin. J. Am. Soc. Nephrol. 2010; 5 (1): 72–79. doi:10.2215/CJN.03860609.; Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann. Intern. Med. 2005; 143 (3): 174–183.; Yazawa M, Kido R, Ohira S, Hasegawa T, Hanafusa N, Iseki K et al. Early mortality was highly and strongly associated with functional status in incident Japanese hemodialysis patients: A cohort study of the large national dialysis registry. PLoS One. 2016; 11 (6): e0156951. doi:10.1371/journal.pone.0156951.; Liu X, Huang R, Wu H, Wu J, Wang J, Yu X, Yang X. Patient characteristics and risk factors of early and late death in incident peritoneal dialysis patients. Sci Rep. 2016; 6: 32359. doi:10.1038/srep32359.; Lukowsky LR, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K. Patterns and Predictors of Early Mortality in Incident Hemodialysis Patients: New Insights. Am. J. Nephrol. 2012; 35 (6): 548–558. doi:10.1159/000338673.; Jain AK, Sontrop JM, Perl J, Blake PG, Clark WF, Moist LM. Timing of peritoneal dialysis initiation and mortality: analysis of the Canadian Organ Replacement Registry. Am. J. Kidney Dis. 2014; 63 (5): 798–805. doi:10.1053/j.ajkd.2013.10.054.; Magalhães LP, dos Reis LM, Graciolli FG, Pereira BJ, de OliveiraRB, de Souza AA et al. Predictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start Hemodialysis. PLoS ONE. 2017; 12 (1): e0167895. doi:10.1371/journal.pone.0167895.; Андрусев АМ, Земченков АЮ. Режим диализа и остаточная функция почек. Нефрология и диализ. 2017; 19 (4): 483–492.; Janmaat CJ, van Diepen M, Krediet RT, Hemmelder MH, Dekker FW. Effect of glomerular fi ltration rate at dialysis initiation on survival in patients with advanced chronic kidney disease: what is the effect of lead-time bias? Clin. Epidemiol. 2017; 9: 217–230. doi:10.2147/CLEP.S127695.; Ramspek CL, Nacak H, van Diepen M, van Buren M, Krediet RT, Rotmans JI et al. NECOSAD Study Group. Pre-dialysis decline of measured glomerular fi ltration rate but not serum creatinine-based estimated glomerular fi ltration rate is a risk factor for mortality on dialysis. Nephrol. Dial. Transplant. 2017; 32 (1): 89–96. doi:10.1093/ndt/gfw236.; Ramspek CL, Voskamp PWM, Krediet RT, Dekker FW, van Diepen M. Prediction models for the mortality risk in chronic dialysis patients: a systematic review and independent external validation study. Nephrol. Dial. Transplant. 2016; 31 (suppl_1): i20. doi:10.1093/ndt/gfw125.01.; van Diepen M, Ramspek CL, Jager KJ, Zoccali C, Dekker FW. Prediction versus aetiology: common pitfalls and how to avoid them. Nephrol. Dial. Transplant. 2017; 32 (suppl_2): ii1–ii5. doi:10.1093/ndt/gfw459.; Яковенко А, Румянцев А, Сомова В. Современный подход к оценке компонентного состава тела у больных на гемодиализе. Врач. 2018; (1): 43–45.; Holme I, Fellström BC, Jardin AG, Schmieder RE, Zannad F, Holdaas H. Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) study. J. Intern. Med. 2012; 271 (5): 463–471. doi:10.1111/j.1365-2796.2011.02435.x.; Mauri JM, Clèries M, Vela E. Catalan Renal Registry. Design and validation of a model to predict early mortality in haemodialysis patients. Nephrol. Dial. Transplant. 2008; 23 (5): 1690–1696. doi:10.1093/ndt/gfm728.; Geddes CC, van Dijk PC, McArthur S, Metcalfe W, Jager KJ, Zwinderman AH et al. The ERA-EDTA cohort study-comparison of methods to predict survival on renal replacement therapy. Nephrol. Dial. Transplant. 2006; 21 (4): 945–956.; Dekker FW, Ramspek CL, van Diepen M. Con: Most clinical risk scores are useless. Nephrol. Dial. Transplant. 2017; 32 (5): 752–755. doi:10.1093/ndt/gfx073.; Wynants L, Collins GS, Van Calster B. Key steps and common pitfalls in developing and validating risk models. BJOG. 2016. doi:10.1111/1471-0528.14170.; Бикбов БТ, Томилина НА. Состав больных и показатели качества лечения на заместительной терапии терминальной хронической почечной недостаточности в Российской Федерации в 1998–2013 гг. Нефрология и диализ. 2016; 18 (2): 98–164.; https://journal.transpl.ru/vtio/article/view/882
-
7Academic Journal
Source: Medical Visualization; № 1 (2017); 103-115 ; Медицинская визуализация; № 1 (2017); 103-115 ; 2408-9516 ; 1607-0763
Subject Terms: почечная недостаточность, contrast -enhanced MDCT, serum creatinine, estimated glome rular filtration rate (eGFR), adverse events, renal failure, МСКТ с контрастным усилением, сывороточный креатинин, расчетная скорость клубочковой фильтрации (рСКФ), побочное действие контрастных средств
File Description: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/382/370; Singh J., Daftary A. Iodinated contrast media and their adverse reactions. J. Nucl. Med. Technol. 2008; 36 (2): 69–74. DOI:10.2967/jnmt.107.047621.; Kwasa E.A., Vinayak S., Armstrong R. The role of inflammation in contrast-induced nephropathy. Br. J. Radiol. 2014; 87 (1041): 20130738. DOI:10.1259/bjr.20130738.; Lasser E.C., Lyon S.G., Berry C.C. Reports on contrast media reactions:analysis of data from reports to the U.S. Food and drug administration. Radiology. 1997; 203: 605–610. DOI:10.1148/radiology.203.3.9169676.; Nash K., Hafeez A., Hou S. Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 2002; 39 (5): 930–936. DOI:10.1053/ajkd.2002.32766.; Chong E., Shen L., Poh K.K., Tan H.C. Risk scoring system for prediction of contrast- induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention. Singapore Med. J. 2012; 53 (3):164–169. PMID: 22434288.; Stacul F., Van der Molen A., Reimer P., Webb J.A., Thomsen H.S., Morcos S.K., Almén T., Aspelin P., Bellin M.F., Clement O., Heinz-Peer G. Contrast induced nephropathy: updated ESUR contrast Media Safety Committee guidelines. Eur. Radiol. 2011; 21 (12): 2527– 2541. DOI:10.1007/s00330-011-2225-0.; Thomsen H.S., Morcos S.K., Barrett B.J. Contrastinduced nephropathy: The wheel has turned 360 degrees. Acta Radiol. 2008; 49 (6):646–657. DOI:10.1080/02841850801995413.; Katzberg R.W., Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int. Suppl. 2006; 69: S3–S7. DOI:10.1038/sj.ki.5000366.; Mehran R., Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int. 2006; 69: S11–S15. DOI:10.1038/sj.ki.5000368.; Berg K.J. Nephrotoxicity related to contrast media. Scand. J. Urol. Nephrol. 2000; 34 (5): 317–322. DOI:10.1080/003655900750048341.; Vercellino M., Bezante G.P., Balbi M. Contrast medium induced nephropathy: new insights into prevention and risk management. Cardiovasc. Hematol. Agents Med. Chem. 2009; 7: 166–180. PMID: 19355877.; Katzberg R.W., Lamba R. Contrast-induced nephropathyafter intravenous administration: fact or fiction? Radiol. Clin. N. Am. 2009; 47 (5): 789–800. DOI:10.1016/j.rcl.2009.06.002.; Kim S.M., Cha R.H., Lee J.P., Oh K.H., Joo K.W., Lim C.S., Kim S., Kim Y.S. Incidence and outcomes of contrastinduced nephropathy after computed tomography in patients with CKD: a quality improvement report. Am. J. Kidney Dis. 2010; 55 (6): 1018–1025. DOI:10.1053/j.ajkd.2009.10.057.; Karlsberg R.P., Dohad S.Y., Sheng R. Contrast-induced acute kidney injury (CI-AKI) following intra-arterial administration of iodinated contrast media. J. Nephrol. 2010; 23 (6): 658–666. PMID: 20540038.; Morcos S.K. Contrast media-induced nephrotoxicity – questions and answers. Br. J. Radiol. 1998; 71: 357–65. DOI:10.1259/bjr.71.844.9659127.; Кармазановский Г.Г., Поляев Ю.А., Юдин А.Л., Шимановский Н.Л. Современные рентгеноконтрастные средства и нефропатия: как снизить риск развития почечной недостаточности? Медицинская визуализация. 2007; 1: 135–144. Karmazanovsky G.G., Poliaev J.A., Judin A.L., Shimanovsky N.L. The Modern X-ray Contrast Agents and Nephropathy: how to Reduce a Hazard of Development of Renal Failure? Meditsinskaya Vizualizatsiya. 2007; 1: 135–144. (In Russian).; Haveman J.W., Gansevoort R.T., Bongaerts A.H., Nijsten M.W. Low incidence of nephropathy in surgical ICU patients receivingintravenous contrast: a retrospective analysis. Intens. Care Med. 2006; 32: 1199–1205. DOI:10.1007/s00134-006-0198-2; Rao Q.A., Newhouse J.H. Risk of nephropathy after intravenousadministration of contrast material: a critical literature analysis. Radiology. 2006; 239: 392–397. DOI:10.1148/radiol.2392050413.; Kooiman J., Pasha S.M., Zondag W., Sijpkens Y.W., van der Molen A.J., Huisman M.V., Dekkers O.M. Metaanalysis: serum creatininechanges following contrast enhanced CT imaging. Eur. J. Radiol. 2012; 81 (10): 2554–2561. DOI:10.1016/j.ejrad.2011.11.020.; Krol A.L., Dzialowski I., Roy J., Puetz V., Subramaniam S., Coutts S.B., Demchuk A.M. Incidence of radiocontrast nephropathy in patients undergoing acute stroke computed tomography angiography. Stroke. 2007; 38: 2364–2366. DOI:10.1161/STROKEAHA.107.482778.; Arana E., Catala-Lуpez F. Contrast-induced nephropathy inpatients at risk of renal failure undergoing computed tomography:systematic review and meta-analysis of randomized controlledtrials. Med. Clin. (Barc.). 2010; 135: 343–350. DOI:10.1016/j.medcli.2010.01.035.; Diogo L.P., Bahlis L.F., Carvalhal G.F. Computerized Tomography contrast induced nephropathy (CIN) among adult inpatients. J. Bras. Nefrol. 2014; 36 (4): 446–450. DOI:10.5935/0101-2800.20140064.; Da Silva Selistre L., de Souza V.C., Dubourg L, Wagner M.B., Filho J.R.H., Saitovitch D. Contrast-induced nephropathy after computed tomography. J. Bras. Nefrol. 2015; 37 (1): 27–31. DOI:10.5935/0101-2800.20150005.; Pucelikova T., Dangas G., Mehran R. Contrast-inducednephropathy. Catheter. Cardiovasc. Interv. 2008; 71 (1): 62–72. DOI:10.1002/ccd.21207.; McCullough P.A., Wolyn R., Rocher L.L., Levin R.N., O’Neill W.W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am. J. Med. 1997; 103 (5): 368–375. PMID: 937570.; El-Hajjar M., Bashir I., Khan M., Min J., Torosoff M., DeLago A. Incidence of contrast- induced nephropathy in patients withchronic renal insufficiency undergoing multidetector computed tomographic angiography treated with preventive measures. Am. J. Cardiol. 2008; 102: 353– 356. DOI:10.1016/j.amjcard.2008.03.0674.; Mehran R., Aymong E.D., Nikolsky E., Lasic Z., Iakovou I., Fahy M., Mintz G.S., Lansky A.J., Moses J.W., Stone G.W., Leon M.B., Dangas G. A simple risk score for prediction of contrast- induced nephropathy afterpercutaneous coronary intervention: development and initial validation. J. Am. Coll. Cardiol. 2004; 44 (7): 1393–1399. DOI:10.1016/j.jacc.2004.06.068.; Toprak O., Cirit M., Yesil M, Bayata S., Tanrisev M., Varol U., Ersoy R., Esi E. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathyin patients with chronic kidney disease. Nephrol. Dial. Transplantat. 2007; 22 (3): 819–826. DOI:10.1093/ndt/gfl636.; Heyman S.N., Rosenberger C., Rosen S., Khamaisi M. Why Is Diabetes Mellitus a Risk Factor for Contrast-Induced Nephropathy? Biomed Res Int. 2013; 2013: 123589. PMCID: PMC3856131 DOI:10.1155/2013/123589.; Pucelikova T., Dangas G., Mehran R. Contrast-induced nephropathy. Catheter. Cardiovasc. Interv. 2008; 71 (1): 62–72. DOI:10.1002/ccd.21207.; Pannu N., Wiebe N., Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. J. Am. Med. Assoc. 2006; 295 (23): 2765–2779. DOI:10.1001/jama.295.23.2765.; Brezis M., Rosen S. Hypoxia of the renal medulla – its implications for disease. N. Engl. J. Med. 1995; 332 (10): 647–655. DOI:10.1056/NEJM199503093321006.; Pallone T.L., Turner M.R., Edwards A., Jamison R.L. Counter current exchange in the renal medulla. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 284 (5): R1153–R1175. DOI:10.1152/ajpregu.00657.2002.; Heyman S.N., Rosen S., Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation and the pathogenesis of radiocontrast nephropathy. Clin. J. Am. Soc. Nephrol. 2008; 3: 288– 296. DOI:10.2215/CJN.02600607.; Katzberg R.W. Contrast medium-induced nephrotoxicity: Which pathway? Radiology. 2005; 235: 752–755. DOI:10.1148/radiol.2353041865.; Heyman S.N., Reichman J., Brezis M. Pathophysioloy of radiocontrast nephropathy. Invest Radiol. 1999; 34: 685–691. PMID: 10548380.; Geenen R.W.F., Kingma H.J., van der Molen A.J. Contrastinduced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging. 2013; 4 (6): 811–820. DOI:10.1007/s13244-013-0291-3.; Heyman S.N., Rosenberger C., Rosen S. Regional alterations inrenal hemodynamcs and oxygenation: a role in contrast medium-induced nephropathy. Nephrol. Dial. Transplant. 2005; 20 (Suppl. 1): i6–i11. DOI:10.1093/ndt/gfh1069.; Katholi R.E., Taylor G.J., McCann W.P., Woods W.T. Jr., Womack K.A., McCoy C.D., Katholi C.R., Moses H.W., Mishkel G.J., Lucore C.L. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology.1995; 195: 17–22. DOI:10.1148/radiology.195.1.7892462.; Deray G., Martinez F., Cacoub P., Baumelou B., Bau melou A., Jacobs C. A role for adenosine, calcium and ischemia in radiocontrast-induced intrarenal vaso constric tion. Am. J. Nephrol. 1990; 10 (4): 316–322. PMID: 2240059.; Persson P.B., Hansell P., Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005; 68 (1): 14–22. DOI:10.1111/j.1523-1755.2005.00377.x.; Haller C., Hizoh I. The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol. 2004; 39 (3): 149–154. PMID: 15076007.; Speck U. Contrast media: overview, use and pharmaceutical aspects, 4th ed. Berlin; Heidelberg; New York: Springer, 1999: 8–83.; Pollack H.M. History of iodinated contrast media. In: Thomson H.S., Muller R.N., Mattrey R.F. (eds). Trends in contrast media. Berlin; Heidelberg; New York: Springer, 1999: 3–19.; Lancelot E., Idee J.M., Lacledere C., Santus R., Corot C. Effects of two dimeric iodinated contrast media on renalmedullary blood perfusion and oxygenation in dogs. Invest. Radiol. 2002; 37 (7): 368–375. PMID: 12068157.; Jost G., Pietsch H., Lengsfeld P., Hutter J., Sieber M.A. The impact of the viscosity and osmolality of iodine contrast agentson renal elimination. Invest. Radiol. 2010; 45 (5): 255– 261. DOI:10.1097/RLI.0b013e3181d4a036.; Seeliger E., Flemming B., Wronski T. Ladwig M., Arakelyan K., Godes M., Mockel M., Persson P. B. Viscosity of contrast media perturbs renal hemodynamics. J. Am. Soc. Nephrol. 2007; 18 (11): 2912–2920. DOI:10.1681/ASN.2006111216.; Liss P., Nygren A., Olsson U., Ulfendahl H.R., Erikson U. Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. Kidney Int. 1996; 49 (5): 1268–1275. PMID: 8731090.; Seeliger E., Sendeski M., Rihal C.S., Persson P.B. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur. Heart J. 2012; 33 (16): 2007–2015. DOI:10.1093/eurheartj/ehr494.; Lenhard D.C., Frisk A.L., Lengsfeld P., Pietsch H., Jost G. Theeffect of iodinated contrast agent properties on renal kinetics and oxygenation. Invest. Radiol. 2013; 48 (4): 175–182. DOI:10.1097/RLI.0b013e31827b70f9.; SmPC texts of the ICMs via the College terBeoordeling vanGeneesmiddelen (Medicines Evaluation Board) in The Netherlandshttp://www.cbg-meb.nl/cbg/nl Last accessed 24/08/2013: Amidotrizoicacid (Urografin); Iobitridol (Xenetix); Iodixanol (Visipaque); Iohexol (Omnipaque); Iomeprol (Iomeron); Iopromide (Ultravist); Ioversol (Optiray); Ioxaglate (Hexabrix); Ioxitalaminic acid (Telebrix).; European Society of Urogenital Radiology contrast media Safety Committee guidelines. Accesible at: http://www.esur.org/guidelines/Last accessed 24/08/2013.; Heinrich M.C., Haberle L., Muller V., Bautz W., Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized-controlled trials. Radiology. 2009; 250 (1): 68–86. DOI:10.1148/radiol.2501080833.; Solomon R.J., Natarajan M.K., Doucet S., Sharma S.K., Staniloae C.S., Katholi R.E., Gelormini J.L., Labinaz M., Moreyra A.E. Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007; 115 (25): 3189–3196. DOI:10.1161/CIRCULATIONAHA.106.671644.; Reed M., Meier P., Tamhane U.U., Welch K.B., Moscucci M., Gurm H.S. The relative renal safety of iodixanol compared with low-osmolar contrast media: a metaanalysis of randomized controlled trials. JACC:Cardiovascular Interv. 2009; 2 (7): 645–654. DOI:10.1016/j.jcin.2009.05.002.; Bolognese L., Falsini G., Schwenke C., Grotti S., Limbruno U., Liistro F., Carrera A., Angioli P., Picchi A., Ducci K., Pierli C. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST- segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following primary Angioplasty for Acute Myocardial Infarction [CONTRASTAMI] trial). Am. J. Cardiol. 2012; 109 (1): 67–74. DOI:10.1016/j.amjcard.2011.08.006.; Aspelin P., Aubry P., Fransson S.G., Strasser R., Willenbrock R., Berg K.J. Nephrotoxic effects in high-risk patients undergoing angiography. New Engl. J. Med. 2003; 348 (6): 491–499. DOI:10.1056/NEJMoa021833.; Chalmers N., Jackson R.W. Comparison of iodixanol andiohexol in renal impairment. Br. J. Radiol. 1999; 72 (859): 701–703. DOI:10.1259/bjr.72.859.10624328.; Dong M., Jiao Z., Liu T., Guo F., Li G. Effect of administration route on the renal safety of contrast agents: a metaanalysis of randomized controlled trials. J. Nephrol. 2012; 25 (3): 290–301. DOI:10.5301/jn.5000067.; Portielje J.E., Kruit W.H., Eerenberg A.J., Schuler M., Sparreboom A., Lamers C.H., Bolhuis R.L., Stoter G., Huber C., Hack C. Interleukin 12 induces activation of fibrinolysis and coagulation in humans. Br. J. Haematol. 2001; 112: 499–505. PMID: 11167854.; Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation,matrix deposition, and female fertility. Annu. Rev. Immunol. 2005; 23: 337–366. DOI:10.1146/annurev.immunol.23.021704.115756.; Du Clos T.W., Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol. Res. 2004; 30 (3): 261–277. DOI:10.1385/IR:30:3:261.; Stouthard J.M., Levi M., Hack C.E., Veenhof C.H., Romijn H.A., Sauerwein H.P., van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb. Haemost. 1996; 76 (5): 738–742. PMID: 8950783.; Cochran S.T., Wong W.S., Roe D.J. Predicting angiography-induced acute renal function impairment: clinical risk model. Am. J. Roentgenol. 1983; 141: 1027–1033. DOI:10.2214/ajr.141.5.1027.; Hassen G.W., Hwang A., Liu L.L., Mualim F., Sembo T., Tu T.J., Wei D.H., Johnston P., Costea A., Meletiche C., Usmani S., Barber A., Jaiswal R., Kalantari H. Follow up for Emergency Department Patients after Intravenous Contrast and Risk of Nephropathy. West J. Emerg. Med. 2014; 15 (3): 276–281. DOI:10.5811/westjem.2013.8.17915.; Lee J., Cho J.Y., Lee H.J. Contrast-induced nephropathy in patients undergoing intravenous contrast-enhanced computed tomography in Korea: a multi-institutional study in 101487 patients. Korean J. Radiol. 2014; 15 (4): 456–463. DOI:10.3348/kjr.2014.15.4.456.; Davenport M.S., Khalatbari S., Cohan R.H., Dillman J.R., Myles J.D., Ellis J.H. Contrast material-induced nephrotoxicity and intravenous low-osmolality contrast material: Risk stratification by usingestimated glomerular filtration rate. Radiology. 2013; 268: 719–728. DOI:10.1148/radiol.13122276.; Park S., Kim M.H., Kang E., Park S., Jo H.A., Lee H., Kim S.M., Lee J.P., Oh K.H., Joo K.W., Kim Y.S., Kim D.K. Contrast-induced nephropathy after computed tomography in stable CKD patients with proper prophylaxis 8-year experience of outpatient prophylaxis program. Medicine (Baltimore). 2016; 95 (18). DOI:10.1097/MD.0000000000003560.; Palli E., Makris D., Papanikolaou J. Contrast-induced nephropathy in aged critically ill patients. Oxid. Med. Cell. Longev. 2014; 2014:756469. DOI:10.1155/2014/756469.; Alsafi A., Alsafi Z., Lakhani A., Strickland N.H. Changes in renal function in elderly patients following intravenous iodinated contrast administration: a retrospective study. Radiol. Res. Pract. 2014; 2014:459583. DOI:10.1155/2014/459583.; Goldenberg I., Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005; 172 (11): 1461–1471. DOI:10.1503/cmaj.1040847.; Sonhaye L., Kolou B., Tchaou M., Amadou A., Assih K., N'Timon B., Adambounou K., Agoda-Koussema L., Adjenou K1, N'Dakena K. Intravenous contrast medium administration for computed tomography scan in emergency: A possible cause of contrast-induced nephropathy. Radiol Res Pract. 2015;2015:805786. DOI:10.1155/2015/805786.; Al-Beladi F.I. Cystatin C is an early marker of contrastinduced nephropathy in patients with sepsis in the intensive care unit. Saudi. J. Kidney. Dis. Transpl. 2015; 26 (4): 718–724. DOI:10.4103/1319-2442.160170.; Solomon R., Barrett B. Follow-up of patients with contrastinduced nephropathy. Kidney. Int. Suppl. 2006; 69: S46– S50. DOI:10.1038/sj.ki.5000374.; Rao Q.A., Newhouse J.H. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology. 2006; 239 (2): 392–397. DOI:10.1148/radiol.2392050413.; Newhouse J.H., Kho D., Rao Q.A., Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. Am. J. Roentgenol. 2008; 191 (2): 376–382. DOI:10.2214/AJR.07.3280.; Bruce R.J., Djamali A., Shinki K., Michel S.J., Fine J.P., Pozniak M.A. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. Am. J. Roentgenol. 2009; 192 (3): 711–718. DOI:10.2214/AJR.08.1413.; Tremblay L.N., Tien H., Hamilton P., Brenneman F.D., Rizoli S.B., Sharkey P.W., Chu P., Rozycki G.S. Risk and benefit of intravenous contrast in trauma patients with an elevated serum creatinine. J. Trauma. 2005; 59 (5):1162– 1166; discussion 1166–1167. PMID: 16385295.; Langner S., Stumpe S., Kirsch M., Petrik M.,Hosten N. No increased risk for contrast- induced nephropathy after multiple CT perfusionstudies of the brain with a nonionic, dimeric, iso-osmolal contrast medium. Am. J. Neuroradiol. 2008; 29 (8): 1525–1529. DOI:10.3174/ajnr.A1164.; Oleinik A., Romero J.M., Schwab K., Lev M.H., Jhawar N., Delgado Almandoz J.E., Smith E.E., Greenberg S.M., Rosand J., Goldstein J.N. CT angiography for intracerebral hemorrhage does not increase risk of acute nephropathy. Stroke. 2009; 40 (7): 2393–2397. DOI:10.1161/STROKEAHA.108.546127.; Bansal G.J., Darby M. Measurement of change in estimated glomerular filtration rate in patients with renal insufficiency aftercontrast-enhanced computed tomography: a case- control study. J. Comput. Assist. Tomogr. 2009; 33 (3): 455–459. DOI:10.1097/RCT.0b013e31818160a3.; Lima F.O., Lev M.H., Levy R.A., Silva G.S., Ebril M., de Camargo É.C., Pomerantz S., Singhal A.B., Greer D.M., Ay H., Gilberto González R., Koroshetz W.J., Smith W.S., Furie K.L. Functional contrast-enhanced CT for evaluation of acute ischemic stroke does not increase the risk of contrast-induced nephropathy. Am. J. Neuroradiol. 2010; 31 (5): 817–821. DOI:10.3174/ajnr.A1927.; McGillicuddy E.A., Schuster K.M., Kaplan L.J., Maung A.A., Lui F.Y., Maerz L.L., Johnson D.C., Davis K.A. Contrast-induced nephropathy in elderly trauma patients. J. Trauma. 2010; 68 (2): 294–297.DOI:10.1097/TA.0b013e3181cf7e40.; Davenport M.S., Khalatbari S., Dillman J.R., Cohan R.H., Caoili E.M., Ellis J.H. Contrast material-induced nephrotoxicity and Intravenous low-osmolality iodinated contrast material. Radiology. 2013; 267: 94–105. DOI:10.1148/radiol.12121394.; American College of Radiology. ACR manualon contrast media. Version 8. 2012.; Elicker B.M., Cypel Y.S., Weinreb J.C. IV contrast administration for CT: a survey of practices for the screening and preventionof contrast nephropathy. Am. J. Roentgenol. 2006; 186 (6): 1651–1658. DOI:10.2214/AJR.05.0407.; Waikar S.S., Bonventre J.V. Creatinine kinetics and the definitionof acute kidney injury. J. Am. Soc. Nephrol. 2009; 20: 672–679. DOI:10.1681/ASN.2008070669.; Soto K., Coelho S., Rodrigues B., Martins H., Frade F., Lopes S., Cunha L., Papoila A.L., Devarajan P. Cystatin C as a marker of acute kidney injury in the emergency department. Clin. J. Am. Soc. Nephrol. 2010; 5 (10): 1745–1754. DOI:10.2215/CJN.00690110.; Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. 2012; Suppl. (2): 1–138.; Ellis J.H., Cohan R.H. Reducing the risk of contrastinduced nephropathy: a perspective on the controversies.Am. J. Roentgenol. 2009; 192 (6): 1544–1549. DOI:10.2214/AJR.09.2368.; Rudnick M., Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clin. J. Am. Soc. Nephrol. 2008; 3 (1): 263–272. DOI:10.2215/CJN.03690907.; Valette X., Parienti J.J., Plaud B., Lehoux P., Samba D., Hanouz J.L. Incidence, morbidity, and mortality of contrast-induced acute kidney injury in a surgical intensive care unit: a prospective cohort study. J. Crit. Care. 2012; 27 (3): 322.e1–322.e5. DOI:10.1016/j.jcrc.2011.08.005.; Laskey W.K., Jenkins C., Selzer F., Marroquin O.C., Wilensky R.L., Glaser R., Cohen H.A., Holmes D.R.Jr. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J. Am. Coll. Cardiol. 2007; 50 (7): 584–590. DOI:10.1016/j.jacc.2007.03.058.; Tan N., Liu Y., Zhou Y.L., He P.C., Yang J.Q., Luo J.F., Chen J.Y. Contrast medium volume to creatinine clearance ratio: a predictor of contrast-induced nephropathy in the first 72 hours following percutaneous coronary intervention. Catheter. Cardiovasc. Interv. 2011; 79 (1): 70–75. DOI:10.1002/ccd.23048.; National Kidney Foundation. K/DOQI clinicalpractice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39 (2, Suppl. 1): S1–S266. PMID: 11904577.; Smith H.W. Comparative physiology of the kidney. The kidney: structure and function in health and disease. New York: Oxford University Press, 1951: 520–574.; ACR Committee on Drugs and Contrast Media. ACR manual on contrast media, version 8. American College of Radiology Website. http://www.acr.org/-/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%. Published 2012. AccessedOctober 8, 2012.; ESUR Contrast Medium Safety Committee. ESUR guidelines on contrast media, version 8.0. European Society of Urogenital Radiology. Web site. http://www.esur.org/guidelines/en/index.php. Published 2012. Accessed November 15, 2012.; Thomsen H.S., Morcos S.K. Risk of contrast mediuminduced nephropathy in high risk patients undergoing MDCT: a pooledanalysis of two randomized trials. Eur. Radiol. 2009; 19 (4): 891–897. DOI:10.1007/s00330-008-1206-4.; Weisbord S.D., Mor M.K., Resnick A.L., Hartwig K.C., Palevsky P.M., Fine M.J. Incidence and outcomes of contrast-induced AKI following computed tomography. Clin. J. Am. Soc. Nephrol. 2008; 3 (5): 1274–1281. DOI:10.2215/CJN.01260308.; https://medvis.vidar.ru/jour/article/view/382
-
8Academic Journal
Source: PULMONOLOGIYA; Том 26, № 2 (2016); 196-200 ; Пульмонология; Том 26, № 2 (2016); 196-200 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2016-26-2
Subject Terms: апелин, glomerular filtration rate, leptin, adiponectin, resistin, apelin, скорость клубочковой фильтрации, расчетная скорость клубочковой фильтрации по CKD-EPI, лептин, адипонектин, резистин
File Description: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/701/612; Минеев В.Н., Трофимов В.И., Садовникова О.М. Бронхиальная астма и хроническая болезнь почек (об щие механизмы). Нефрология. 2015; 2: 27–32.; Teta D. Adipokines as uremic toxins. J. Ren Nutr. 2012; 22 (1): 81–85.; Минеев В.Н., Зеленкова З.А., Садовникова О.М. Ско рость клубочковой фильтрации при различных вариан тах бронхиальной астмы. Пульмонология. 2015; 5: 593–599.; Минеев В.Н., Лалаева Т.М., Васильева Т.С., Кузьми на А.А. Лептин и адипонектин при бронхиальной аст ме. Цитокины и воспаление. 2015; 1: 68–75.; Минеев В.Н., Лалаева Т.М., Кузьмина А.А. Ассоциация апелина 12, адипонектина, лептина и резистина при аллергической бронхиальной астме – использование интегральных индексов. Иммунопатология, аллергология, инфектология. 2015; 1: 30–34.; Минеев В.Н., Лалаева Т.М., Трофимов В.И. Адипоки новая сигнализация при бронхиальной астме. СПб: ВВМ; 2016.; Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. СПб: Левша; 2012.; Mitsnefes M., Kartal J., Khoury P., Daniels S. Adiponectin in children with chronic kidney disease: role of adiposity and kidney dysfunction. Clin. J. Am. Soc. Nephrol. 2007; 2: 46–50.; Guebre Egziabher F., Bernhard J., Funahashi T. et al. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol. Dial. Transplant. 2005; 20: 129–134.; Miyamoto S., Sharma K. Adipokines protecting CKD. Nephrol. Dial. Transplant. 2013; 28 (Suppl. 4): iv15–iv22.; Deshmukh S., Srivastava S., Bhardwaj A. et al. Resistin and interleukin 6 exhibit racially disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget. 2015; 6 (13): 11231–11241.; Mafra D., Guebre Egziabher F., Fouque D. Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol. Dial. Transplant. 2008; 23 (8): 2461–2466.; Минеев В.Н., Лалаева Т.М., Васильева Т.С., Трофи мов В.И. Фенотип бронхиальной астмы с ожирением. Пульмонология. 2012; 2: 102–107.; Pandya D., Puttanna A., Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir. Med. J. 2014; 8: 59–65.; Briffa J.F., McAinch A.J., Poronnik P., Hryciw D.H. Adipo kines as a link between obesity and chronic kidney disease. Am. J. Physiol. Renal Physiol. 2013; 305 (12): F1629–1636.; Rüster C., Wolf G. Adipokines promote chronic kidney dis ease. Nephrol. Dial. Transplant. 2013; 28 (Suppl. 4): iv8–14.; Chuang P.Y., He J.C. JAK/STAT signaling in renal diseases. Kidney Int. 2010; 78 (3): 231–234.; Минеев В.Н., Сорокина Л.Н., Трофимов В.И. Фундаментальные и клинические аспекты JAK STAT сигнализации. СПб: BBM; 2010.; Pang M., Ma L., Gong R. et al. A novel STAT3 inhibitor, S3I 201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 2010; 78 (3): 257–268.; Brosius F.C. 3rd, He J.C. JAK inhibition and progressive kid ney disease. Curr. Opin. Nephrol. Hypertens. 2015; 24 (1): 88–95.; https://journal.pulmonology.ru/pulm/article/view/701
-
9Report
Authors: Baran, Lütfi, Baştemir, Mehmet, Türkmen, Serdar
Subject Terms: Insulin-treated diabetes mellitus, лечимый инсулином, сахарный диабет, estimated glomerular filtration rate, расчетная скорость клубочковой фильтрации, drug-eluting stent, ишемическая болезнь сердца, coronary artery disease, 3. Good health, стент с лекарственным покрытием
-
10Academic Journal
Authors: KOBALAVA ZH.D., VILLEWALDE S.V., EFREMOVTSEVA M.A.
Source: Kardiologiia
Subject Terms: microalbuminuria, calculated glomerular filtration rate, subclinical renal involvement, nonproteinuric nephropathy, микроальбуминурия, расчетная скорость клубочковой фильтрации, субклиническое поражение почек, непротеинурическая нефропатия
Availability: https://repository.rudn.ru/records/article/record/124322/